Creative Bioarray and Oxford Gene Technology form partnership to advance biomarkers for the early diagnosis of pancreatic cancer

Creative Bioarray has today announced a collaboration with Oxford Gene Technology, aimed at improving the early detection of pancreatic cancer.

Creative Bioarray, a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases, and Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, today announced a collaboration aimed at improving the early detection of pancreatic cancer.

As part of this collaboration, Creative Bioarray will provide data mining expertise to deliver optimal sample sets from its large prospective serum biobank, taken from individuals up to 7 years before the diagnosis of pancreatic cancer. OGT will apply its functional protein array platform and its Genefficiency microRNA profiling array to identify pancreatic cancer specific biomarkers that can be used as diagnostic indicators of developing pancreatic cancer. Both OGT and Creative Bioarray will bring their expertise in experimental design and analysis.

Dr.Chen, the Chief Executive Officer, Creative Bioarray said: “We are very excited to be able to form this strategic partnership with OGT. The combination of the breadth of the OGT technology with our unique serum biobank provides a real opportunity to significantly advance the field of early pancreatic cancer diagnosis and screening. ”

John Anson, Vice President Biomarker Discovery, OGT said: “A common challenge in discovering novel cancer biomarkers is the availability of well characterised samples for the disease area of interest. We are delighted that, through our partnership with Creative Bioarray, we are able to employ our unique and integrated genomic and proteomic array technologies to identify sensitive and specific biomarkers for pancreatic cancer.”
Financial details were not disclosed

ABOUT Creative Bioarray

Creative Bioarray is a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases. The company’s prospective biobank has over 5,000,000 serum samples derived from more than 200,000 initially healthy volunteers, 50,000 of whom have provided samples annually, making this an ideal resource for identifying biomarkers for disease screening.

Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.

Clinical & Genomic Solutions: OGT’s GenefficiencyTM is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSureTM cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.


About sharly

sharly's blog is a group about the intersection of art, science, biology,nature and geek culture.
This entry was posted in news and tagged , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s